QUAD Investment Management

HoneyNaps is a company that specializes in developing a bio-signal monitoring device aimed at treating sleep disorders. Their platform is designed to collect and analyze various data points during sleep, including body temperature, heart rate, breathing patterns, and movement. This information is then used by medical professionals and researchers to detect any abnormal symptoms and take appropriate action.

NeoCannBio provides natural product processing facilities for generating new medications derived from natural goods and built a cannabinoid library of hemp, and medical cannabis.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Good Food For Good operates as a food & lifestyle brand company.

Avelos Therapeutics is a clinical-stage precision medicine company specializing in the development of targeted therapeutics for cancer treatment. They focus on creating biomarker-driven therapies centered around cell cycle regulation, DNA damage response, and historically 'undruggable' cancer targets. The company aims to enable more effective cancer treatments by identifying and targeting specific biomarkers.

KaliVir Immunotherapeutics is a biopharmaceutical company focused on developing innovative oncolytic viral immunotherapy products aimed at treating various tumor types. Utilizing a next-generation vaccinia platform, KaliVir enhances systemic delivery capabilities, enabling targeted replication and spread of the virus within the tumor microenvironment. The company’s approach integrates technologies both developed in-house and licensed from the University of Pittsburgh, leveraging cutting-edge research in oncolytic viruses and immunotherapy. With a focus on tailored transgene programs, KaliVir offers healthcare professionals powerful tools designed to improve the effectiveness of cancer treatments through its proprietary genetic modifications.

Curiox Biosystems Pte. Ltd. is a bioinstrumentation company that specializes in the development and commercialization of innovative assay platforms aimed at advancing the life sciences, drug discovery, and diagnostics. Established in 2007 and headquartered in Singapore, Curiox offers a range of products designed to enhance the efficiency and automation of bioassays, including DropArray microplates for miniaturized assays and Laminar Wash technology for automated cell processing. Its product lineup includes various washing stations, microplates, fluids, and accessories tailored for applications such as bead-based immunoassays, suspension cell assays, high-content assays, and iPS cell research. Leveraging expertise in surface chemistry and engineering, Curiox is committed to overcoming challenges in life science research through improved automation and reproducibility.

Pear Therapeutics, Inc. is a Boston-based commercial-stage healthcare company specializing in software-based digital therapeutics, also known as Prescription Digital Therapeutics (PDTs). Founded in 2013, the company develops clinically validated software solutions designed to treat a range of behavioral health disorders, including addiction, anxiety, depression, and chronic insomnia. Its suite of products includes mobile digital therapies that reward patients for engagement, and specific tools like reSET and reSET-O, aimed at treating substance use disorders. The company also offers Somryst, which provides neurobehavioral interventions for insomnia, and operates PearConnect, a patient services center that connects patients with advocates and resources, ensuring support throughout their treatment journey. Pear Therapeutics aims to enhance treatment outcomes by integrating digital therapies with pharmaceuticals and providing comprehensive support for patients, clinicians, and payors.

Bisu is a health technology company that offers a home health lab designed to enhance personal well-being through urine and saliva tests. Its devices monitor various health metrics, including dietary health, fat metabolism, and hydration levels, providing users with daily feedback on electrolytes, hydration, pH, ketones, and uric acid via a mobile application. This functionality enables individuals to track burned body fat, maintain metabolic health, achieve optimal ketosis, and improve physical endurance. Bisu has received recognition for its innovation, having been awarded by prestigious organizations such as Johnson & Johnson Innovation and MedTech Innovator, and it gained further acclaim at CES 2020 with the IHS Markit Innovation Award.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital medicine solutions. The company's core business involves creating video game-based technology to assess and enhance cognitive abilities. Akili's broad pipeline focuses on treating cognitive deficiencies and improving symptoms associated with various medical conditions, such as ADHD, MDD, ASD, and inflammatory diseases.

Medipixel, Inc. is a South Korean MedTech startup founded in 2017, specializing in artificial intelligence-based diagnostic software and semi-autonomous robotic systems for lung cancer and cardiac interventions. The company is comprised of a team of AI experts in computer vision, deep learning, and reinforcement learning, collaborating with top healthcare professionals, including those at Seoul Asan Medical Center, to enhance disease diagnosis and surgical procedures. Medipixel offers three primary solutions for intervention surgeons: an AI-based diagnosis tool that assists in identifying lesions during coronary angiography, a guide and planning solution that visualizes coronary arteries to facilitate guidewire manipulation, and an automated navigation engine that directs robotic units through arteries with real-time commands. These innovations aim to improve surgical outcomes and patient safety by reducing reliance on contrast agents and enhancing the precision of interventions.

Pear Therapeutics, Inc. is a Boston-based commercial-stage healthcare company specializing in software-based digital therapeutics, also known as Prescription Digital Therapeutics (PDTs). Founded in 2013, the company develops clinically validated software solutions designed to treat a range of behavioral health disorders, including addiction, anxiety, depression, and chronic insomnia. Its suite of products includes mobile digital therapies that reward patients for engagement, and specific tools like reSET and reSET-O, aimed at treating substance use disorders. The company also offers Somryst, which provides neurobehavioral interventions for insomnia, and operates PearConnect, a patient services center that connects patients with advocates and resources, ensuring support throughout their treatment journey. Pear Therapeutics aims to enhance treatment outcomes by integrating digital therapies with pharmaceuticals and providing comprehensive support for patients, clinicians, and payors.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company based in Emeryville, California, focused on developing innovative gene therapies for unmet medical needs. The company utilizes targeted and evolved adeno-associated virus (AAV) vectors to create its product candidates, which are concentrated in the therapeutic areas of ophthalmology, cardiology, and pulmonology. Key candidates in its portfolio include 4D-125, currently in a Phase I/II trial for X-linked retinitis pigmentosa, and 4D-110, undergoing Phase I trials for choroideremia. Additionally, 4D-310 is in Phase I/II trials for Fabry disease, while investigational drugs 4D-150 and 4D-710 are being developed for wet age-related macular degeneration and cystic fibrosis lung disease, respectively. Founded in 2013, 4D Molecular Therapeutics aims to advance its gene therapies to address significant health challenges.

Korea Credit Data Co., Ltd. is a Seoul-based company that specializes in developing business management software, particularly for small and medium enterprises. Founded in 2016, its flagship product, CashNote, enables users to manage card payment schedules, conduct customer analysis, and perform tax invoice inquiries. In addition to CashNote, Korea Credit Data offers a range of services that include customer analysis, point-of-sale (POS) systems, and payment solutions through its various subsidiaries. The company serves over two million businesses in Korea, aiming to address challenges faced by business owners throughout their operational lifecycle. By forming strategic partnerships with leading industry players, Korea Credit Data has established a strong market presence and expanded its offerings to include payment networks and credit bureau services, enhancing its ability to support its clients effectively.

Medipixel, Inc. is a South Korean MedTech startup founded in 2017, specializing in artificial intelligence-based diagnostic software and semi-autonomous robotic systems for lung cancer and cardiac interventions. The company is comprised of a team of AI experts in computer vision, deep learning, and reinforcement learning, collaborating with top healthcare professionals, including those at Seoul Asan Medical Center, to enhance disease diagnosis and surgical procedures. Medipixel offers three primary solutions for intervention surgeons: an AI-based diagnosis tool that assists in identifying lesions during coronary angiography, a guide and planning solution that visualizes coronary arteries to facilitate guidewire manipulation, and an automated navigation engine that directs robotic units through arteries with real-time commands. These innovations aim to improve surgical outcomes and patient safety by reducing reliance on contrast agents and enhancing the precision of interventions.

Curiox Biosystems Pte. Ltd. is a bioinstrumentation company that specializes in the development and commercialization of innovative assay platforms aimed at advancing the life sciences, drug discovery, and diagnostics. Established in 2007 and headquartered in Singapore, Curiox offers a range of products designed to enhance the efficiency and automation of bioassays, including DropArray microplates for miniaturized assays and Laminar Wash technology for automated cell processing. Its product lineup includes various washing stations, microplates, fluids, and accessories tailored for applications such as bead-based immunoassays, suspension cell assays, high-content assays, and iPS cell research. Leveraging expertise in surface chemistry and engineering, Curiox is committed to overcoming challenges in life science research through improved automation and reproducibility.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Oncorus, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead product candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently undergoing Phase I clinical trials to assess its efficacy against various cancers. In addition to ONCR-177, Oncorus is advancing its ONCR-GBM program aimed at treating brain cancer, along with synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. The company has established a clinical trial collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s KEYTRUDA immunotherapy. Founded in 2015, Oncorus is committed to improving patient outcomes and has pledged to contribute a portion of its product sales to support cancer research and care in developing regions.

Korea Credit Data Co., Ltd. is a Seoul-based company that specializes in developing business management software, particularly for small and medium enterprises. Founded in 2016, its flagship product, CashNote, enables users to manage card payment schedules, conduct customer analysis, and perform tax invoice inquiries. In addition to CashNote, Korea Credit Data offers a range of services that include customer analysis, point-of-sale (POS) systems, and payment solutions through its various subsidiaries. The company serves over two million businesses in Korea, aiming to address challenges faced by business owners throughout their operational lifecycle. By forming strategic partnerships with leading industry players, Korea Credit Data has established a strong market presence and expanded its offerings to include payment networks and credit bureau services, enhancing its ability to support its clients effectively.

ABL Bio Inc. is a biotechnology research company based in Seongnam, South Korea, dedicated to the development of therapeutic drugs aimed at treating immuno-oncology and neurodegenerative diseases. The company's pipeline includes several innovative products, such as ABL001, a bispecific antibody for cancer immunotherapy, and ABL301, designed to penetrate the blood-brain barrier. ABL Bio also focuses on antibody-drug conjugates and dual immune cell targeting bispecific antibodies, reflecting its commitment to advancing novel therapies in the biotech sector. Through its research and development efforts, ABL Bio aims to improve patients' lives by delivering effective and innovative treatment options.